ARCA biopharma (ABIO)
(Delayed Data from NSDQ)
$3.58 USD
+0.10 (2.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.54 -0.04 (-1.12%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for ARCA biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 7 | 11 | 19 | 10 | 6 |
Income After Depreciation & Amortization | -7 | -11 | -19 | -10 | -6 |
Non-Operating Income | 2 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -5 | -10 | -19 | -10 | -6 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -5 | -10 | -19 | -10 | -5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -5 | -10 | -19 | -10 | -5 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -7 | -10 | -19 | -10 | -6 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -7 | -11 | -19 | -10 | -6 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 14.42 | 14.41 | 13.90 | 4.71 | 1.32 |
Diluted EPS Before Non-Recurring Items | -0.37 | -0.69 | -1.39 | -2.07 | -4.15 |
Diluted Net EPS (GAAP) | -0.37 | -0.69 | -1.39 | -2.07 | -4.15 |
Fiscal Year end for ARCA biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.59 | 1.94 | 1.97 | 1.80 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.59 | -1.94 | -1.97 | -1.80 |
Non-Operating Income | NA | 0.50 | 0.51 | 0.49 | 0.45 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.09 | -1.42 | -1.48 | -1.35 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.09 | -1.42 | -1.48 | -1.35 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.09 | -1.42 | -1.48 | -1.35 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 14.44 | 14.41 | 14.41 | 14.41 |
Diluted EPS Before Non-Recurring Items | NA | -0.08 | -0.10 | -0.10 | -0.09 |
Diluted Net EPS (GAAP) | NA | -0.08 | -0.10 | -0.10 | -0.09 |